Biotech

Cassava Sciences Begins Phase 2b Study in Alzheimer’s patients

Biotech

The company’s initiation of the Phase 2b study follows the positive results reported from a Phase 2a study.

Cassava Sciences (NASDAQ:SAVA) has announced it has begun a Phase 2b study of its lead candidate, PTI-125 in Alzheimer’s patients.

As quoted in the press release:

PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful. This Phase 2b study is supported by a research grant award from the National Institutes of Health (NIH).

“There is a profound and timely need to develop new drug therapies for this devastating disease,” said Remi Barbier, President & CEO. “We are pleased to advance PTI-125 into this randomized, placebo-controlled study in approximately 60 Alzheimer’s patients, and are eager to report how results of this study will expand upon the clinical data set for PTI-125.”

Initiation of the Phase 2b study follows the positive results reported from a Phase 2a study, demonstrating 100% responder rate and statistically significant decreases in key biomarkers of Alzheimer’s pathology, neuroinflammation and neurodegeneration.

Click here to read the full press release.

MARKETS

Markets
TSX20544.35-84.57
TSXV617.94+4.34
DOW33749.79-141.23
S&P 5004097.32-13.76
NASD11863.91-23.54
ASX7539.00-19.10

COMMODITIES

Commodities
Gold1868.03-0.14
Silver22.16-0.11
Copper4.01-0.03
Palladium1713.170.00
Platinum1087.260.00
Oil75.34+1.23
Heating Oil2.83+0.07
Natural Gas2.55+0.09

DOWNLOAD FREE REPORTS

×